Current PharmacoGenomics 1
Transcript of Current PharmacoGenomics 1
-
8/7/2019 Current PharmacoGenomics 1
1/20
Mirza Ahmed Hammad
Changing the world to
individual Drugs managementsystem
PharmacoGenomics
Roll No: 1255 Session 2007-2011
D
e pa
rt
men
t
Of
Bio-In
forma
tics
-
8/7/2019 Current PharmacoGenomics 1
2/20
Pharmacogenomics
The study of genome-derived data to predict abodys response to a drug or susceptibility to adisease:
Human genetic variation in DNA Single nucleotide polymorphisms (SNPs)
Copy number differences
Insertions
Deletions
Duplications Rearrangements
RNA and protein expression differences
-
8/7/2019 Current PharmacoGenomics 1
3/20
Drugs costs are
escalating!
-
8/7/2019 Current PharmacoGenomics 1
4/20
Drug efficacy is questioned..
-
8/7/2019 Current PharmacoGenomics 1
5/20
UK ADRs Study
6.5% of new hospital admissions to internal medicinewards are directly related to ADRs!(1,225 admi
ssions out of 18,820 during six months)
4% of bed occupancy - directly due to ADRs
Annual UK cost: EUR 706 million(direct hospitalization costs - actual costs muchhigher!)
Women: 59% of ADRs (while only 52% of admissions)
Pirmohamed et al (July 2004) Adverse drug reactions as cause of admission tohospital: prospective analysis of 18 820 patients. BMJ. 329:15-19.
-
8/7/2019 Current PharmacoGenomics 1
6/20
Treat:
Responders and PatientsNot Predisposed to Toxicity
All patients with same diagnosis
Remove:(1) non-responders(2) toxic responders
Which is more urgent?
What should our prioritiesbe?
-
8/7/2019 Current PharmacoGenomics 1
7/20
Improving drug efficacyDifficulties with ensuring better Drug Efficacy:
Tailoring the most effective drug and dosage for theindividual patient is extremely complex.(exception: in oncology some success)
Hundreds of polymorphic gene alleles are involved
Many non-genetic factors participate in drugefficacy:
Gender; age; environment; diet; physical activity;smoking; family support etc.
d f li d
-
8/7/2019 Current PharmacoGenomics 1
8/20
Are we Ready for PersonalizedMedicine?
Better Drug Efficacy? Not Yet!
We are not yet ready, with few exceptions:- Oncology (Herceptin, anti-EGFR)
- Depression (5-HTT genotyping)
- High blood pressure Bidil (FDA approved June 2005)(ethnic considerations in drug prescription as an interimphase ACE inhibitors ineffective in African-Americans,preference for NO donors & calcium channel inhibitors)
In most medical disciplines, we are not likely to be ready for
Personalized Medicine in the clinic before 2025;maybe only ~2050? but there will be exceptions..
-
8/7/2019 Current PharmacoGenomics 1
9/20
Medicine
If we focus first on better drug
safetyConsideration #1: Society almost ready..- Growing public awareness on costs of drug toxicity(both economic costs and human suffering)
- Growing awareness of genetic factors affecting health
for complex diseases (not just for genetic disorders)
- Worries about the graying of society and theassociated soaring health care costs in the EU and USA
-
8/7/2019 Current PharmacoGenomics 1
10/20
(Almost) Ready for PersonalizedMedicineConsideration #2: Government almost ready
Drug regulatory agencies are (almost) ready:USA: In March 2005, the FDA has issued the
Guidance forIndustry: Pharmacogenomic Data Submissions
http://www.fda.gov/cber/gdlns/pharmdtasub.htm
Europe: In February 2005, WHO/CIOMS WorkingGroup on
Pharmacogenetics has issued the report,Pharmacogenetics
Towards improving treatment with medicines(Council for International Organizations of Medical
Sciences)
http://www.fda.gov/cber/gdlns/pharmdtasub.htmhttp://www.fda.gov/cber/gdlns/pharmdtasub.htm -
8/7/2019 Current PharmacoGenomics 1
11/20
Medicine
If we focus first on better drug
safetyConsideration #3: Pharmaceutical Industry Pharma, which traditionally objected to PGx as a threat
to market size and profits, begin to see the advantages:
- Lower costs for clinical trials (less participants)- New orphaned markets- Can charge more for safer drugs
- Marketing a diagnostic test along with the drugcan bring added revenues
-
8/7/2019 Current PharmacoGenomics 1
12/20
Medicine
If we focus first on better drug
safetyConsideration #4: Diagnostic Tools
Diagnostic tools focusing on better drug
safety have been approved by the FDA anthe EC and are entering the market:
Roche Diagnostics AmpliChip P450:
- approved by the EC in September 2004,and by the FDA
in December 2004
li hi
-
8/7/2019 Current PharmacoGenomics 1
13/20
AmpliChip CYP450: CYP2D6 &CYP2C19
-
8/7/2019 Current PharmacoGenomics 1
14/20
urren rac ce: r a anError
- What about Safety?
Toxicity No Effect
Oops!Oops!Too Much Too Little
Decrease dose Increase dose
No effect
Increase doseor change drug
Toxicity
Decrease doseor change drug
Favorable Effect
-
8/7/2019 Current PharmacoGenomics 1
15/20
Drug Pharmacokinetics
-
8/7/2019 Current PharmacoGenomics 1
16/20
DepressionThe most prevalent affective disorder:
10%-20% of the population (lifetime)
Decreased rapheserotonin
Excessive activity ofthe serotonintransporter??
-
8/7/2019 Current PharmacoGenomics 1
17/20
Health, Genes, & Society:Where do we go from here?
Should we oblige industry to do'something' for people who do not
have the right genotype for theirdrug? What should it include?
How can society ensure better equalityin healthcare, along withindividualization of
pharmacotherapy?
-
8/7/2019 Current PharmacoGenomics 1
18/20
Personalized Medicine:
Not if, rather: when?
Opinion: This sort of card would initially (~2025?) includemostly information related to drug metabolizing enzymes
Around ~2050 it might include an entire individualgenome(or at least, few millions SNPs..)
In your wallet by2025?
Or maybe by 2050?
[New
-
8/7/2019 Current PharmacoGenomics 1
19/20
ere s my sequence... [NewYorker]Are we ready?
Not quite yet! Weneed: Comprehensive data
Affordablegenotyping tools Professional
Education Solving ethical issues!
Meanwhile, we should
-
8/7/2019 Current PharmacoGenomics 1
20/20
REFERENCES & Conclusion Although it is expected to take another decade for
PharmacoGenomics to be an accepted and integral part ofmainstream healthcare, but with the help of other Biologicalgroups attached with the Genomes could catapult theindustry into the public consciousness. Drugs based onindividual testing can be more effective giving required or
near to required results. For this there is a need of developingnew Biomarkers, Cell responses, Biotechnology tools and Bio-Informatics tools, so that diagnosis and screening of a diseasecould easily be done.
References are given with CD.
Thanks!